Sarah C. Akerman
Psychiatry
1 Medical Center Dr
Dhmc Department Of Psychiatry
Lebanon, NH 03756
Dhmc Department Of Psychiatry
Lebanon, NH 03756
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Olanzapine/Samidorphan Effects on Weight Gain: An Individual Patient Data Meta-Analysis of Phase 2 and 3 Randomized Double-Blind Studies.
Journal: The Journal of clinical psychiatry
Published: January 20, 2025
Opioid antagonists: clinical utility, pharmacology, safety, and tolerability.
Journal: CNS spectrums
Published: November 25, 2024
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.
Journal: Schizophrenia bulletin
Published: October 28, 2022
Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder.
Journal: BMC psychiatry
Published: October 14, 2022
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine.
Journal: CNS spectrums
Published: March 03, 2022
Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
Journal: The American journal of drug and alcohol abuse
Published: November 09, 2021
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.
Journal: Drug and alcohol dependence
Published: October 04, 2021
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Journal: The American journal on addictions
Published: December 28, 2020
Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018.
Journal: Drug safety
Published: November 09, 2020
Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Journal: Addiction (Abingdon, England)
Published: May 29, 2020
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Journal: The American journal on addictions
Published: October 04, 2019
Last Updated: 09/26/2026